Retrospective assessment of secondary prophylaxis for invasive aspergillosis in neutropenic hematology patients and identification of risk factors for relapse of fungal disease

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 7, 2013, Pages 531-536

  Kikuchi, Misato ^a   Nakasone, Hideki ^a   Mitani, Kinuko ^b   Gotoh, Moritaka ^c   Kobayashi, Ayako ^d   Kurita, Naoki ^e   Saito, Takeshi ^f   Sato, Ken ^d   Kanda, Yoshinobu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^e IBARAKI UNIVERSITY   (Japan)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Invasive aspergillosis; Neutropenia; Secondary prophylaxis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; VORICONAZOLE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; GRAFT FAILURE; HEMATOLOGIC DISEASE; HUMAN; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; LYMPHOCYTE COUNT; LYMPHOMA; MALE; MEDICAL RECORD REVIEW; NEUTROPENIA; PROPHYLAXIS; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SECONDARY PROPHYLAXIS; SEPSIS; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CHEMOPREVENTION; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MIDDLE AGED; NEUTROPENIA; RECURRENCE; RISK FACTORS; YOUNG ADULT;

EID: 84879078828     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2013.776173     Document Type: Review

References (11)

1. C aira M, C andoni A, O ffi dani M, F ianchi L, Martino B, et al. The epidemiology of fungaLinfections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
2. Sipsas N V, K ontoyiannis D P. C linicaLissues regarding relapsing aspergillosis and the effi cacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis 2006; 42: 1584-91.
3. De Pauw B, W alsh T J, D onnelly J P, S tevens DA, Edwards JE, Calandra T, et al. Revised defi nitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive FungaLinfections Cooperative Group and the NationaLinstitute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
4. Herbrecht R, D enning DW, P atterson TF, B ennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
5. Black S, K ushner I, S amols D. C-reactive protein. J Biol Chem 2004; 279: 48487-90.
6. Fine JP, G ray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
7. Cordonnier C, R ovira M, M aertens J, O lavarria E, F aucher C, Bilger K, et al. Voriconazole for secondary prophylaxis of invasive fungaLinfections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010; 95: 1762-8.
8. Allinson K, K olve H, G umbinger H G, V ormoor H J, E hlert K, Groll AH. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother 2008; 61: 734-42.
9. Fukuda T, B oeckh M, G uthrie KA, M attson DK, O wens S, Wald A, et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004; 10: 494-503.
10. Freifeld AG, B ow EJ, S epkowitz KA, B oeckh MJ, I to JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56-93.
11. Cattaneo C, Monte S, A lgarotti A, Audisio E, Borlenghi E, Campiotti L, et al. A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study). J Antimicrob Chemother 2011; 66: 2140-5.